Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Research and Innovation Action · Running

BRIDGE Breakthrough Regulatory Innovation and Development throuGh sandbox Environments

Coordinator
Vlaamse Instelling Voor Technologisch Onderzoek N.v., Belgium
Runs
1 November 2025 to 31 October 2028
Status
Running
EU funding
€5.2m
Total cost
€9.4m
Partners
42 organisations in 12 countries
Type
Research and Innovation Action
Grant agreement
101219311

What the project is doing

In the project's own words, from its summary on CORDIS.

BRIDGE aims to enhance healthcare innovation in Europe by developing a comprehensive framework for designing and operationalizing regulatory sandboxes. By addressing current regulatory limitations and engaging all stakeholders while ensuring compliance, the project seeks to create adaptable, fit-for-purpose methodologies that strengthen the regulatory ecosystem's capacity to promote healthcare innovation. The project’s objectives include identifying and analysing existing regulatory sandboxes across various domains and maturity levels, to determine how their modules can complement current healthcare regulations.

BRIDGE will develop a horizon scanning methodology to continuously identify emerging technologies that challenge existing regulatory systems, analyzing their requirements for potential inclusion in regulatory sandboxes to ensure adaptability within an evolving innovation ecosystem. Through multi-stakeholder consultations, BRIDGE will elaborate and assess case studies, as well as develop operational checklists for module design and evidence packages to guide tailored sandbox launches.

The project will also develop the Modular Operational Sandbox for Healthcare Innovation and Compliance (MOSAIC), an architectural model with interconnected modules featuring detailed functional specifications and mapped information flows aligned with specific case studies. Additionally, BRIDGE will engage key stakeholders—including regulatory bodies, industry consortia, HTA bodies, payers, healthcare providers, and patients—in an in-depth analysis, consultation, and consensus-building process to ensure the sandbox approach is comprehensive, functional, and adaptable to future advancements.

Finally, the project will deliver comprehensive recommendations for the sandbox methodology’s end-to-end operations, encompassing legal, compliance, policy, and regulatory outputs to provide a robust implementation framework.

Who is involved

OrganisationCityCountryRole
Vlaamse Instelling Voor Technologisch Onderzoek N.v.MolBelgiumCoordinator
Federation Europeenne D'associations Et D'industries PharmaceutiquesBruxellesBelgiumParticipant
Janssen Pharmaceutica NVBeerseBelgiumParticipant
MSD Europe BelgiumBrusselsBelgiumAssociatedpartner
The European Association Medical Devices-Notified BodiesSprimontBelgiumParticipant
The European Institute for Innovation Through Health DataGentbruggeBelgiumParticipant
F. Hoffmann-La Roche AGBaselSwitzerlandParticipant
Novartis Pharma AGBaselSwitzerlandParticipant
Takeda Pharmaceuticals International AGGlattparkSwitzerlandParticipant
Bundesinstitut Fur Arzneimittel Und MedizinprodukteBonnGermanyParticipant
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Csl Behring GmbHMarburgGermanyParticipant
Empirica Gesellschaft Fur Kommunikations Und Technologieforschung MbhBonnGermanyParticipant
Euroscan International Network eVKolnGermanyParticipant
Lilly Deutschland GmbHBad HomburgGermanyAssociatedpartner
Merck Healthcare KgaaDarmstadtGermanyAssociatedpartner
Merck Kommanditgesellschaft Auf AktienDarmstadtGermanyParticipant
Merckle GmbHBlaubeurenGermanyAssociatedpartner
Pfizer Pharma GmbHBerlinGermanyAssociatedpartner
Sanofi-Aventis Deutschland GmbHFrankfurt Am MainGermanyAssociatedpartner
Technische Universitaet DresdenDresdenGermanyParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Fundacion Publica Andaluza Progreso Y Salud M.p.SevillaSpainParticipant
Merck, Sharp & Dohme de España, S.A.MadridSpainAssociatedpartner
Teknologian Tutkimuskeskus VTT OyEspooFinlandParticipant
Sanofi R&d VaccinsLyonFranceAssociatedpartner
Sanofi Winthrop IndustrieGentillyFranceAssociatedpartner
Sanofi-Aventis Recherche & DeveloppementGentillyFranceParticipant
Universite Bourgogne EuropeDijonFranceParticipant
Pfizer Healthcare Ireland Unlimited CompanyDublinIrelandAssociatedpartner
Teva Pharmaceutical Industries LimitedPetach TivkaIsraelParticipant
Academisch Ziekenhuis GroningenGroningenNetherlandsParticipant
Astellas Pharma Europe BVLeidenNetherlandsParticipant
The European Medicines AgencyAmsterdamNetherlandsParticipant
Biogen Idec LimitedMaidenheadUnited KingdomParticipant
Eli Lilly and Company LtdBasingstokeUnited KingdomAssociatedpartner
Msd R&d Innovation Centre LimitedLondonUnited KingdomAssociatedpartner
Merck Serono Ltd.FelthamUnited KingdomAssociatedpartner
Pfizer R&D UK LimitedSandwichUnited KingdomAssociatedpartner
Eli Lilly and CompanyIndianapolisUnited StatesParticipant
Merck Sharp & Dohme CorpWhitehouse Station NjUnited StatesParticipant
Pfizer IncNew York CityUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI